Vendor Analysis
published on Jun 17, 2016
Report Overview:
This NelsonHall vendor assessment analyzes NTT Data's offerings and capabilities in software testing.
Who is this Report for:
NelsonHall’s software testing vendor assessment for NTT Data is a comprehensive assessment of NTT Data’s testing offerings and capabilities designed for:
- Sourcing managers monitoring the capabilities of existing suppliers of IT services and identifying vendor suitability for software testing services
- Vendor marketing, sales and business managers looking to benchmark themselves against their peers
- Financial analysts and investors specializing in the software testing sector.
Scope of this Report:
The report provides a comprehensive and objective analysis of NTT Data’s software testing offerings, capabilities, and market and financial strength, including:
- Analysis of the company’s offerings and key service components
- Revenue estimates
- Identification of the company’s strategy, emphasis and new developments
- Analysis of the profile of the company’s customer base including the company’s targeting strategy and examples of current contracts
- Analysis of the company’s strengths, weaknesses and outlook.
Key Findings & Highlights:
NTT Data is a major Japan based IT services firm: in CY 2015 it had revenues of ~$12.4bn. NTT Data is Japan’s largest IT service pure-play. It is primarily an application service company and is part of the NTT Group, which, in addition to telecom services, provides mostly IT infrastructure services through Dimension Data.
As part of its NTT Data Global One program, it has started coordinatingits different geography-led testing practices in terms of solutioning, IPs and tools. Currently, the largest testing practices are in North America, Japan and Spain.
NTT Data has 10.8k career testers, representing ~15% of its global headcount. NelsonHall estimates its CY 2015 revenues from testing work delivered by career testers at ~$0.9bn.
NTT Data derives ~40% of its testing revenues from BFSI, 25% from manufacturing, and 20% from public sector/healthcare/life sciences.